Ronald Hunt - Net Worth and Insider Trading

Ronald Hunt Net Worth

The estimated net worth of Ronald Hunt is at least $81 Million dollars as of 2024-05-12. Ronald Hunt is the Former 10% beneficial owner of Relypsa Inc and owns about 2,114,890 shares of Relypsa Inc (RLYP) stock worth over $68 Million. Ronald Hunt is the Director of Rallybio Corp and owns about 4,449,360 shares of Rallybio Corp (RLYB) stock worth over $8 Million. Ronald Hunt is also the Director, 10% Owner of Harpoon Therapeutics Inc and owns about 224,284 shares of Harpoon Therapeutics Inc (HARP) stock worth over $5 Million. Besides these, Ronald Hunt also holds Iterum Therapeutics PLC (ITRM) . Details can be seen in Ronald Hunt's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Ronald Hunt has not made any transactions after 2021-08-02 and currently still holds the listed stock(s).

Transaction Summary of Ronald Hunt

Ronald Hunt Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Ronald Hunt owns 12 companies in total, including Iterum Therapeutics PLC (ITRM) , Harpoon Therapeutics Inc (HARP) , and Neuronetics Inc (STIM) among others .

Click here to see the complete history of Ronald Hunt’s form 4 insider trades.

Insider Ownership Summary of Ronald Hunt

Ticker	Comapny	Transaction Date	Type of Owner
ITRM	Iterum Therapeutics PLC	2019-06-13	director & 10 percent owner
HARP	Harpoon Therapeutics Inc	2021-01-11	director & 10 percent owner
STIM	Neuronetics Inc	2018-06-27	director & 10 percent owner
		2016-10-19	10 percent owner
		2012-12-18	10 percent owner
		2014-03-20	10 percent owner
		2013-04-10	10 percent owner
		2014-02-12	10 percent owner
		2013-11-27	other: Former 10% Beneficial Owner
		2013-11-20	director & other: Former 10% beneficial owner
		2011-07-13	10 percent owner
		2021-08-02	director

Ronald Hunt Latest Holdings Summary

Ronald Hunt currently owns a total of 4 stocks. Among these stocks, Ronald Hunt owns 2,114,890 shares of Relypsa Inc (RLYP) as of November 20, 2013, with a value of $68 Million and a weighting of 83.41%. Ronald Hunt owns 4,449,360 shares of Rallybio Corp (RLYB) as of August 2, 2021, with a value of $8 Million and a weighting of 10.04%. Ronald Hunt also owns 224,284 shares of Harpoon Therapeutics Inc (HARP) as of January 11, 2021, with a value of $5 Million and a weighting of 6.36%. The other 1 stocks Iterum Therapeutics PLC (ITRM) have a combined weighting of 0.19% among all his current holdings.

Latest Holdings of Ronald Hunt

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
RLYP	Relypsa Inc	2013-11-20	2,114,890	31.99	67,655,331
RLYB	Rallybio Corp	2021-08-02	4,449,360	1.83	8,142,329
HARP	Harpoon Therapeutics Inc	2021-01-11	224,284	23.01	5,160,775
ITRM	Iterum Therapeutics PLC	2018-05-30	97,087	1.55	150,485

Holding Weightings of Ronald Hunt

Ronald Hunt Form 4 Trading Tracker

According to the SEC Form 4 filings, Ronald Hunt has made a total of 0 transactions in Relypsa Inc (RLYP) over the past 5 years. The most-recent trade in Relypsa Inc is the acquisition of 185,978 shares on November 20, 2013, which cost Ronald Hunt around $2 Million.

According to the SEC Form 4 filings, Ronald Hunt has made a total of 1 transactions in Rallybio Corp (RLYB) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Rallybio Corp is the acquisition of 307,692 shares on August 2, 2021, which cost Ronald Hunt around $4 Million.

According to the SEC Form 4 filings, Ronald Hunt has made a total of 1 transactions in Harpoon Therapeutics Inc (HARP) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Harpoon Therapeutics Inc is the acquisition of 23,529 shares on January 11, 2021, which cost Ronald Hunt around $4 Million.

More details on Ronald Hunt's insider transactions can be found in the Insider Trading History of Ronald Hunt table.

Insider Trading History of Ronald Hunt

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Ronald Hunt Trading Performance

GuruFocus tracks the stock performance after each of Ronald Hunt's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ronald Hunt is 38.96%. GuruFocus also compares Ronald Hunt's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ronald Hunt within 3 months outperforms 2 times out of 5 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Ronald Hunt's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Ronald Hunt

Average Return

Average return per transaction

Outperforming Transactions

2 out of 5 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	9.17
Relative Return to S&P 500(%)	7.17

Ronald Hunt Ownership Network

Ownership Network List of Ronald Hunt

No Data

Ownership Network Relation of Ronald Hunt

Ronald Hunt Owned Company Details

What does Iterum Therapeutics PLC do?

Who are the key executives at Iterum Therapeutics PLC?

Ronald Hunt is the director & 10 percent owner of Iterum Therapeutics PLC. Other key executives at Iterum Therapeutics PLC include Chief Scientific Officer Michael W. Dunne , director & President & CEO Fishman Corey N. , and Chief Medical Officer Sailaja Puttagunta .

Iterum Therapeutics PLC (ITRM) Insider Trades Summary

Over the past 18 months, Ronald Hunt made no insider transaction in Iterum Therapeutics PLC (ITRM). Other recent insider transactions involving Iterum Therapeutics PLC (ITRM) include a net purchase of 55,000 shares made by Michael W. Dunne , a net purchase of 10,000 shares made by Fishman Corey N. , and a net sale of 3,365 shares made by Sailaja Puttagunta .

In summary, during the past 3 months, insiders sold 0 shares of Iterum Therapeutics PLC (ITRM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 3,365 shares of Iterum Therapeutics PLC (ITRM) were sold and 65,000 shares were bought by its insiders, resulting in a net purchase of 61,635 shares.

Iterum Therapeutics PLC (ITRM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Iterum Therapeutics PLC Insider Transactions

No Available Data

What does Harpoon Therapeutics Inc do?

Who are the key executives at Harpoon Therapeutics Inc?

Ronald Hunt is the director & 10 percent owner of Harpoon Therapeutics Inc. Other key executives at Harpoon Therapeutics Inc include 10 percent owner Vijay K Lathi , Chief Medical Officer Luke Nathaniel Walker , and Principal Fin. & Acctng Ofc. Frank J Lanza .

Harpoon Therapeutics Inc (HARP) Insider Trades Summary

Over the past 18 months, Ronald Hunt made no insider transaction in Harpoon Therapeutics Inc (HARP). Other recent insider transactions involving Harpoon Therapeutics Inc (HARP) include a net purchase of 21,397,205 shares made by Merck & Co., Inc. ,

In summary, during the past 3 months, insiders sold 0 shares of Harpoon Therapeutics Inc (HARP) in total and bought 21,397,205 shares, with a net purchase of 21,397,205 shares. During the past 18 months, 0 shares of Harpoon Therapeutics Inc (HARP) were sold and 21,397,205 shares were bought by its insiders, resulting in a net purchase of 21,397,205 shares.

Harpoon Therapeutics Inc (HARP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Harpoon Therapeutics Inc Insider Transactions

No Available Data

What does Neuronetics Inc do?

Who are the key executives at Neuronetics Inc?

Ronald Hunt is the director & 10 percent owner of Neuronetics Inc. Other key executives at Neuronetics Inc include Sr. VP & GC & CCO and Secretary William Andrew Macan , CFO Stephen Furlong , and director & President and CEO Keith J Sullivan .

Neuronetics Inc (STIM) Insider Trades Summary

Over the past 18 months, Ronald Hunt made no insider transaction in Neuronetics Inc (STIM). Other recent insider transactions involving Neuronetics Inc (STIM) include a net sale of 145,432 shares made by William Andrew Macan , a net sale of 336,027 shares made by Cannell Capital Llc , and a net sale of 105,543 shares made by Stephen Furlong .

In summary, during the past 3 months, insiders sold 155,132 shares of Neuronetics Inc (STIM) in total and bought 0 shares, with a net sale of 155,132 shares. During the past 18 months, 961,359 shares of Neuronetics Inc (STIM) were sold and 224,736 shares were bought by its insiders, resulting in a net sale of 736,623 shares.

Neuronetics Inc (STIM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Neuronetics Inc Insider Transactions

No Available Data

What does iRhythm Technologies Inc do?

Who are the key executives at iRhythm Technologies Inc?

Ronald Hunt is the 10 percent owner of iRhythm Technologies Inc. Other key executives at iRhythm Technologies Inc include CLO & EVP RA/QA MrktAcs & Gov Patrick Michael Murphy , Chief Financial Officer Brice Bobzien , and EVP & CMO & CSO Minang Turakhia .

iRhythm Technologies Inc (IRTC) Insider Trades Summary

Over the past 18 months, Ronald Hunt made no insider transaction in iRhythm Technologies Inc (IRTC). Other recent insider transactions involving iRhythm Technologies Inc (IRTC) include a net sale of 20,569 shares made by Daniel G. Wilson , a net sale of 13,101 shares made by Patrick Michael Murphy , and a net sale of 5,504 shares made by Mark J. Day .

In summary, during the past 3 months, insiders sold 42,096 shares of iRhythm Technologies Inc (IRTC) in total and bought 0 shares, with a net sale of 42,096 shares. During the past 18 months, 76,173 shares of iRhythm Technologies Inc (IRTC) were sold and 9,755 shares were bought by its insiders, resulting in a net sale of 66,418 shares.

iRhythm Technologies Inc (IRTC)'s detailed insider trading history can be found in Insider Trading Tracker table.

iRhythm Technologies Inc Insider Transactions

No Available Data

What does MEI Pharma Inc do?

Who are the key executives at MEI Pharma Inc?

Ronald Hunt is the 10 percent owner of MEI Pharma Inc. Other key executives at MEI Pharma Inc include Chief Medical Officer Richard G Ghalie , 10 percent owner Amin Nathoo , and 10 percent owner Funicular Funds, Lp .

MEI Pharma Inc (MEIP) Insider Trades Summary

Over the past 18 months, Ronald Hunt made no insider transaction in MEI Pharma Inc (MEIP). Other recent insider transactions involving MEI Pharma Inc (MEIP) include a net purchase of 201,660 shares made by Anson Funds Management Lp , a net purchase of 134,440 shares made by Funicular Funds, Lp , and a net purchase of 81,500 shares made by Baltic Charles V. Iii .

In summary, during the past 3 months, insiders sold 0 shares of MEI Pharma Inc (MEIP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of MEI Pharma Inc (MEIP) were sold and 340,175 shares were bought by its insiders, resulting in a net purchase of 340,175 shares.

MEI Pharma Inc (MEIP)'s detailed insider trading history can be found in Insider Trading Tracker table.

MEI Pharma Inc Insider Transactions

No Available Data

What does Aravive Inc do?

Who are the key executives at Aravive Inc?

Ronald Hunt is the 10 percent owner of Aravive Inc. Other key executives at Aravive Inc include Chief Commercial Officer Maria Carolina Petrini , Chief Medical Officer Robert B. Geller , and Chief Financial Officer Rudy Howard .

Aravive Inc (ARAV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aravive Inc (ARAV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aravive Inc (ARAV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aravive Inc (ARAV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aravive Inc Insider Transactions

No Available Data

What does Chimerix Inc do?

Who are the key executives at Chimerix Inc?

Ronald Hunt is the 10 percent owner of Chimerix Inc. Other key executives at Chimerix Inc include Principal Accounting Officer David Jakeman , Chief Business Officer Michael T. Andriole , and director & Chief Executive Officer Michael A. Sherman .

Chimerix Inc (CMRX) Insider Trades Summary

Over the past 18 months, Ronald Hunt made no insider transaction in Chimerix Inc (CMRX). Other recent insider transactions involving Chimerix Inc (CMRX) include a net purchase of 60,000 shares made by Fred A Middleton , a net sale of 9,500 shares made by David Jakeman , and a net purchase of 87,000 shares made by Michael A. Sherman .

In summary, during the past 3 months, insiders sold 6,344 shares of Chimerix Inc (CMRX) in total and bought 0 shares, with a net sale of 6,344 shares. During the past 18 months, 13,184 shares of Chimerix Inc (CMRX) were sold and 173,750 shares were bought by its insiders, resulting in a net purchase of 160,566 shares.

Chimerix Inc (CMRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Chimerix Inc Insider Transactions

No Available Data

What does Concert Pharmaceuticals Inc do?

Who are the key executives at Concert Pharmaceuticals Inc?

Ronald Hunt is the 10 percent owner of Concert Pharmaceuticals Inc. Other key executives at Concert Pharmaceuticals Inc include Chief Development Officer James V Cassella , CFO & PFO Marc A. Becker , and Chief Operating Officer Nancy Stuart .

Concert Pharmaceuticals Inc (CNCE) Insider Trades Summary

Over the past 18 months, Ronald Hunt made no insider transaction in Concert Pharmaceuticals Inc (CNCE). Other recent insider transactions involving Concert Pharmaceuticals Inc (CNCE) include a net sale of 16,093 shares made by Nancy Stuart , a net sale of 12,999 shares made by James V Cassella , and a net sale of 11,386 shares made by Jeffrey A Munsie .

In summary, during the past 3 months, insiders sold 0 shares of Concert Pharmaceuticals Inc (CNCE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 61,104 shares of Concert Pharmaceuticals Inc (CNCE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 61,104 shares.

Concert Pharmaceuticals Inc (CNCE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Concert Pharmaceuticals Inc Insider Transactions

No Available Data

What does Oxford Immunotec Global PLC do?

Who are the key executives at Oxford Immunotec Global PLC?

Ronald Hunt is the other: Former 10% Beneficial Owner of Oxford Immunotec Global PLC. Other key executives at Oxford Immunotec Global PLC include director & Chief Executive Officer Peter Wrighton-smith , Chief Financial Officer Mclaughlin Matthew T E , and Chief Operating Officer Stefan C Linn .

Oxford Immunotec Global PLC (OXFD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Oxford Immunotec Global PLC (OXFD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Oxford Immunotec Global PLC (OXFD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Oxford Immunotec Global PLC (OXFD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Oxford Immunotec Global PLC Insider Transactions

No Available Data

What does Relypsa Inc do?

Who are the key executives at Relypsa Inc?

Ronald Hunt is the director & other: Former 10% beneficial owner of Relypsa Inc. Other key executives at Relypsa Inc include SVP & Chief Commercial Officer J. Scott Garland , SVP & Chief Technology Officer Wilhelm Stahl , and See Remarks Ronald A. Krasnow .

Relypsa Inc (RLYP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Relypsa Inc (RLYP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Relypsa Inc (RLYP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Relypsa Inc (RLYP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Relypsa Inc Insider Transactions

No Available Data

What does Paratek Pharmaceuticals Inc do?

Who are the key executives at Paratek Pharmaceuticals Inc?

Ronald Hunt is the 10 percent owner of Paratek Pharmaceuticals Inc. Other key executives at Paratek Pharmaceuticals Inc include CLO & General Counsel & Sec. William M. Haskel , President & Chief Commercial Adam Woodrow , and Chief Development & Regulatory Randall B. Brenner .

Paratek Pharmaceuticals Inc (PRTK) Insider Trades Summary

Over the past 18 months, Ronald Hunt made no insider transaction in Paratek Pharmaceuticals Inc (PRTK). Other recent insider transactions involving Paratek Pharmaceuticals Inc (PRTK) include a net sale of 172,206 shares made by Evan Loh , a net sale of 98,375 shares made by Michael Bigham , and a net sale of 79,527 shares made by William M. Haskel .

In summary, during the past 3 months, insiders sold 0 shares of Paratek Pharmaceuticals Inc (PRTK) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 442,355 shares of Paratek Pharmaceuticals Inc (PRTK) were sold and 788,500 shares were bought by its insiders, resulting in a net purchase of 346,145 shares.

Paratek Pharmaceuticals Inc (PRTK)'s detailed insider trading history can be found in Insider Trading Tracker table.

Paratek Pharmaceuticals Inc Insider Transactions

No Available Data

What does Rallybio Corp do?

Who are the key executives at Rallybio Corp?

Ronald Hunt is the director of Rallybio Corp. Other key executives at Rallybio Corp include 10 percent owner 5am Partners V, Llc , director & 10 percent owner Kush Parmar , and See Remarks Jonathan I Lieber .

Rallybio Corp (RLYB) Insider Trades Summary

Over the past 18 months, Ronald Hunt made no insider transaction in Rallybio Corp (RLYB). Other recent insider transactions involving Rallybio Corp (RLYB) include a net sale of 100,000 shares made by 5am Partners V, Llc , and a net sale of 100,000 shares made by Kush Parmar .

In summary, during the past 3 months, insiders sold 0 shares of Rallybio Corp (RLYB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 200,000 shares of Rallybio Corp (RLYB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 200,000 shares.

Rallybio Corp (RLYB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rallybio Corp Insider Transactions

No Available Data

Ronald Hunt Mailing Address

Above is the net worth, insider trading, and ownership report for Ronald Hunt. You might contact Ronald Hunt via mailing address: C/o Credit Suisse 1st Boston Prv Eqy, 11 Madison Avenue, New York Ny 10010.

Discussions on Ronald Hunt

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.